ARTICLE | Company News

Eutropics, Tolero Pharmaceuticals deal

January 20, 2014 8:00 AM UTC

The companies partnered to use Eutropics' Praedicare-Dx biomarker platform to predict responses to Tolero's compounds to treat hematological malignancies, including alvocidib (flavopiridol). The Praedicare-Dx identifies alterations in apoptosis signaling pathways in cancer cells and stratifies leukemia and myeloma patients based on the likelihood of responding to treatment. Alvocidib is in Phase II testing to treat acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), indolent lymphoma/myeloma and germ cell tumors. The partners will also collaborate with Johns Hopkins University (Baltimore, Md.) to carry out clinical correlation studies of alvocidib in combination with cytarabine in AML patients. Eutropics said it will receive an upfront payment and funding. Tolero could not be reached for details. ...